Literature DB >> 2459368

Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell.

B J Undem1, P T Peachell, L M Lichtenstein.   

Abstract

The inhibitory effect of isoproterenol was examined on the release of histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2) from human lung mast cells. Isoproterenol was more potent in inhibiting anti-immunoglobulin (Ig) E-induced LTC4 and PGD2 release than histamine release from the dispersed lung cell preparations (2-5% mast cells). The negative log molar EC50 values of isoproterenol for inhibiting histamine, LTC4 and PGD2 release were 8.2 +/- 0.2, 8.9 +/- 0.2 and 8.7 +/- 0.3, respectively (mean +/- S.E.M., n = 8). Isoproterenol seldom inhibited histamine release by more than 60%, but usually abolished the release of LTC4 and PGD2. The potency of propranolol (KB = 6 X 10(-10) M) was the same for competitively antagonizing isoproterenol mediated inhibition of histamine, LTC4 or PGD2 release. Using the irreversible beta adrenergic receptor antagonist, bromoacetylalprenololmenthane, the estimated dissociation constant of isoproterenol was 2 X 10(-7) M irrespective of whether inhibition of anti-IgE-induced histamine or LTC4 release was examined. When the divalent cation ionophore A23187 was used to induce histamine release, isoproterenol had either no effect or potentiated the release. In contrast, isoproterenol was capable of virtually abolishing A23187-induced LTC4 release. Qualitatively similar effects of isoproterenol were observed on purified mast cell preparations (greater than 80% mast cells); however, the potency of isoproterenol in inhibiting mediator release from these preparations was reduced. The results demonstrate that there is a substantial receptor reserve for isoproterenol-mediated inhibition of histamine, LTC4 and PGD2 release from the human lung mast cell. The intrinsic efficacy of isoproterenol in inhibiting anti-IgE-induced release of arachidonic acid metabolites is approximately 3 times greater than that for inhibiting histamine release.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459368

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Regulation of mast cells by beta-agonists.

Authors:  Peter Peachell
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 2.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

3.  Prevention by phosphodiesterase inhibitors of antigen-induced contraction of guinea-pig colonic smooth muscle.

Authors:  M Grous; M Barnette
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

Review 4.  Recent contributions to knowledge of the mechanism of action of nimesulide.

Authors:  M Bevilacqua; E Magni
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells.

Authors:  Anne-Marie Scola; Matthew Loxham; Steven J Charlton; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

6.  Effects of beta 2-adrenergic agonists on isolated guinea pig lung mast cells.

Authors:  H Y Lau; P L Wong; C K Lai
Journal:  Agents Actions       Date:  1994-10

7.  Optimizing drug inhibition of IgE-mediated anaphylaxis in mice.

Authors:  Suzanne C Morris; Charles Perkins; Crystal Potter; David Parsons; Richard Schuman; Marat V Khodoun; Unni Samavedam; Richard Strait; Fred D Finkelman
Journal:  J Allergy Clin Immunol       Date:  2021-06-26       Impact factor: 14.290

8.  Association of beta 2-adrenergic receptor polymorphism with the phenotype of aspirin-intolerant acute urticaria.

Authors:  Hyoun-Ah Kim; Young-Min Ye; Seung-Hyun Kim; Gyu-Young Hur; Hae-Sim Park
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

9.  Cyclic-AMP mediated drugs: differential or global reduction of eicosanoid synthesis in the isolated rat lung?

Authors:  M J Post; J D Biesebeek; J Wemer; H H Rooij; F J Zijlstra; A J Porsius
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.